Clinical Trial Update: Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

This update reports on a Phase 2/Phase 3 trial evaluating the addition of carboplatin to neoadjuvant therapy for patients with triple-negative and HER2-positive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II | Phase 2, Phase 3 | Status: COMPLETED